$MCK · MCKESSON CORP
McKesson reported Q2 FY2026 (quarter ended September 30, 2026) results: revenue of $110.957B, up 8% YoY; GAAP diluted EPS of $10.44 (up 17%); adjusted diluted EPS of $11.68 (up 18%). The company raised full-year FY2027 adjusted EPS guidance to $45.60–$46.40 from $44.20–$45.00, implying 17%–19% growth. Cash from operations was $3.1B with $2.9B free cash flow for the quarter.
- Revenue $110.957B, up 8% YoY from $103.15B.
- Adjusted diluted EPS $11.68, up 18% from $9.86.
- GAAP diluted EPS $10.44, up 17% from $8.92.
- FY2027 adjusted EPS guidance raised to $45.60–$46.40.
- Q2 cash from operations $3.1B; free cash flow $2.9B.
Stock closed +6.87% at $1,068.31; extended-hours last trade $1,056.00, -1.15% vs regular close, a modest giveback after the strong session.
A guidance raise plus double-digit adjusted EPS growth signals durable operating momentum across McKesson's core distribution and specialty segments.
McKesson's 8% revenue growth and double-digit adjusted EPS growth reflect continued strength in pharmaceutical distribution and specialty, outpacing typical distributor growth.
Planned Medical-Surgical Solutions separation and Option Care Health investment are subject to conditions and may not close on contemplated terms or timeline. Opioid-related litigation and other legal disputes remain ongoing risks.